Molecular Classification of Persistent Fever: Advances in Diagnosis and Management

Abstract

Persistent fever represents a complex clinical challenge, often signaling a diverse array of underlying pathologies. Recent advances in molecular diagnostics have revolutionized the approach to persistent fever by enabling more precise etiological classification based on pathogen genomics, host response profiles, and disease-specific molecular markers. This review synthesizes current evidence on the molecular classification of persistent fever, discusses its clinical implications, and explores emerging strategies for diagnosis and management, emphasizing the importance of an integrated, evidence-based approach for improved patient outcomes.

Introduction

Persistent fever—defined as a febrile state lasting beyond seven days without an identifiable cause after initial evaluation—remains a significant diagnostic dilemma in clinical practice. Traditional diagnostic frameworks, often reliant on clinical and basic laboratory findings, may be insufficient to elucidate the etiology, especially in cases of fever of unknown origin (FUO) or atypical presentations. The integration of molecular biology and omics technologies has reshaped the landscape, providing powerful tools for pathogen detection, immune profiling, and risk stratification. This article reviews the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, and management of persistent fever, with a focus on molecular classification and its practical relevance for clinicians.

Epidemiology / Disease Burden

Persistent fever accounts for approximately 2–5% of all hospital admissions in developed countries and is a leading cause of prolonged hospitalization, especially in immunocompromised populations. The etiological spectrum varies with geography, patient demographics, and healthcare resources, encompassing infectious, autoimmune, neoplastic, and miscellaneous causes. In low- and middle-income countries, infections such as tuberculosis and typhoid fever predominate, whereas non-infectious etiologies, including connective tissue diseases and malignancies, are increasingly recognized in high-income settings. The global burden is compounded by diagnostic delays, empirical therapies, and associated morbidity, demanding robust, targeted approaches for early and accurate diagnosis.

Pathophysiology

At the molecular level, persistent fever results from sustained pyrogenic signaling, typically mediated by endogenous cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferons. These mediators are released in response to exogenous pathogens or endogenous triggers such as autoantigens or neoplastic cells. Molecular characterization enables differentiation between infectious, inflammatory, and neoplastic fevers by identifying distinctive biomarker signatures. For example, procalcitonin and C-reactive protein (CRP) are often elevated in bacterial infections, while interferon-gamma signatures may indicate viral or autoimmune origins. Advances in genomics, transcriptomics, and proteomics further refine the classification by revealing pathogen-specific DNA/RNA or host gene expression profiles, facilitating targeted interventions.

Risk Factors

Risk factors for persistent fever are multifactorial and include immunosuppression (e.g., neutropenia, HIV/AIDS, organ transplantation), advanced age, chronic comorbidities (such as diabetes mellitus or chronic kidney disease), and exposure to endemic pathogens. Hospitalization itself may predispose to nosocomial infections, while recent travel, occupational exposures, or underlying malignancy should raise suspicion for specific etiologies. Genetic predispositions, such as mutations in autoinflammatory syndrome genes (e.g., MEFV, NLRP3), can also manifest as recurrent or persistent fever, underscoring the importance of personalized molecular assessment.

Clinical Features

The clinical presentation of persistent fever is highly variable, often lacking pathognomonic signs. Common features include sustained elevated body temperature, malaise, weight loss, night sweats, and, depending on etiology, organ-specific symptoms such as lymphadenopathy, hepatosplenomegaly, rash, or arthralgia. In immunocompromised patients, symptoms may be subtle or masked, necessitating a high index of suspicion and a molecularly informed diagnostic approach. Temporal patterns (continuous, remittent, intermittent) and associated laboratory abnormalities (e.g., cytopenias, elevated inflammatory markers) can guide further workup.

Diagnosis

The diagnostic strategy for persistent fever increasingly incorporates molecular-based techniques alongside conventional investigations. Polymerase chain reaction (PCR) assays, next-generation sequencing (NGS), and multiplex pathogen panels enable rapid identification of bacterial, viral, fungal, and parasitic agents, even in culture-negative cases. Host gene expression profiling, microarray analysis, and proteomic signatures can distinguish between infectious and non-infectious causes, providing actionable insights. For example, a "host response score" based on RNA signatures can differentiate bacterial from viral infections with high sensitivity and specificity. Integration of these molecular tools with clinical algorithms and imaging enhances diagnostic accuracy and reduces unnecessary empirical therapy.

Treatment & Management

Management of persistent fever hinges on accurate etiological classification. Empirical antimicrobial therapy remains standard for suspected infections but carries risks of resistance and adverse effects if misapplied. Molecular diagnostics allow early de-escalation or targeted escalation of therapy. In autoimmune or autoinflammatory disorders, immune-modulating agents (e.g., corticosteroids, biologics targeting IL-1 or IL-6) are guided by molecular and serological markers. Malignancy-associated fevers may require cytotoxic or targeted oncologic therapies. Supportive care, vigilant monitoring for complications, and interdisciplinary collaboration are essential components of management, especially in complex or immunocompromised patients.

Recent Advances / Emerging Therapies

Recent years have witnessed transformative advances in the molecular classification of persistent fever. Metagenomic NGS enables unbiased pathogen discovery, while digital PCR offers high-sensitivity quantification of microbial load. Host transcriptome panels and cytokine profiling facilitate rapid differentiation of infectious versus inflammatory fevers. Machine learning algorithms applied to molecular and clinical datasets are being developed to predict etiology and guide personalized therapy. Novel therapeutics, such as JAK inhibitors for autoinflammatory syndromes and monoclonal antibodies targeting specific cytokines, represent promising additions to the therapeutic armamentarium. Ongoing clinical trials are evaluating the utility and cost-effectiveness of these molecular innovations in routine care.

Guideline Recommendations

International guidelines, including those from the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), increasingly advocate for the integration of molecular diagnostics in the evaluation of persistent fever, particularly in immunocompromised hosts and FUO cases. Recommendations emphasize a stepwise approach, starting with broad-based molecular assays in high-risk patients, followed by targeted testing based on clinical context and epidemiology. Early involvement of infectious diseases specialists, rheumatologists, and oncologists is advised for multidisciplinary assessment and management. The need for judicious use of molecular tests to balance diagnostic yield with cost and resource constraints is highlighted across guidelines.

Conclusion

Molecular classification has fundamentally altered the diagnostic and therapeutic paradigm for persistent fever. By integrating pathogen detection, host response profiling, and disease-specific markers, clinicians can achieve earlier, more accurate diagnoses and implement targeted interventions. Continued advances in molecular technologies, coupled with evidence-based guidelines, promise to further improve outcomes for patients with persistent fever. Ongoing research and interdisciplinary collaboration will be critical to translating these innovations into routine clinical practice, reducing morbidity, and enhancing patient care.